Navigation Links
BioElectronics Corporation Receives Major Orders From Italian Distributor
Date:5/5/2008

ActiPatch(TM) Chosen as A Safe and Effective Alternative to NSAIDs, Such As

Vioxx(R) and Celebrex(R)

FREDERICK, Md., May 5 /PRNewswire-FirstCall/ -- BioElectronics Corporation (Pink Sheets: BIEL), the maker of the ActiPatch(TM), a drug free anti-inflammatory patch, with an embedded battery operated microchip delivering weeks of continuous pulsed therapy for a nickel an hour, announced today it has received significant new orders from its Italian distributor, TSS Medical, (Tecnica Scientifica Service). TSS Medical has purchased this additional inventory to meet demand in Italy and other European Union counties. BioElectronics is seeing demand for its product increase significantly in Western Europe, which combined with expanding sales in the U.S. and other countries, is likely to drive quarterly revenues to record levels.

Andrew Whelan, President and CEO of BioElectronics Corp. comments, "These are exciting times for all of us at BioElectronics. We expect demand from Italy to increase over the coming months as the product is rolled out to pharmacies across the country. We have also expanded the relationship with our Italian partner to include distribution to additional areas in Europe for which we have now received an initial stocking order. Many Europeans are very interested in the drug-free nature of our products at a time when NSAIDs, such as Vioxx(R) and Celebrex(R), have been determined to have potentially serious cardiovascular side effects. We believe health consumers with pain and soft tissue injuries will continue to view our proven, state-of-the-art ActiPatch therapy as an effective alternative to pharmaceuticals."

About BioElectronics Corporation

Bioelectronics Corporation is the maker of the ActiPatch(TM). ActiPatch is a drug free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective patient friendly method to reduce soft tissue pain and swelling. ActiPatch is U.S. Government Food and Drug Administration (FDA) cleared for use in reducing edema (swelling) following blepharoplasty and has no known side effects. The product is also approved by Health Canada for the relief of pain in musculoskeletal complaints and is widely available in pharmacies across Canada. The European Union has also approved ActiPatch as a Class II pulsed electromagnetic medical device as have numerous other international regulatory agencies. Information on ActiPatch and BioElectronics Corp. is available at the following websites:

-- U.S. Consumer http://www.actipatchonline.com

-- Podiatry: http://www.pemfpodiatry.com

-- Plastic Surgery: http://www.plasticsurgery.com and http://www.makemeheal.com

-- German orthopedic foot & ankle: http://www.diesfussexperten.de

-- Italy and Switzerland: http://www.actipatch.it

-- BioElectronics Corp: http://www.bioelectronicscorp.com

Safe Harbor Statement

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies In light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the company has no control.

Vioxx(R) is a registered trademark of Merck & Company

Celebrex(R) is a registered trademark of Pfizer Inc

Media Contact:

Patricia Baker, The Big Picture Agency LLC

Voice: 413-623-0950 ext. 221, email: pbaker@bigpictureagency.com

Investor Relations Contact:

Joe Noel, Emerging Growth Research LLP

Voice: 925-922-2560, email: jnoel701@emerginggrow.com


'/>"/>
SOURCE BioElectronics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioElectronics Corporation Announces Singapore and Malaysia Sales
2. BioElectronics Corporation Announces Distribution Agreement With TSS Medical of Italy
3. BioElectronics Announces Canadian Retail Product Launch
4. BioElectronics Launches 1 Day Breast Augmentation Recovery Kit
5. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
9. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
10. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
11. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... Tunnell Consulting, ... Based in Paris, he will focus on acquiring new accounts and work closely ... , “Fred brings to our European clients more than 15 years ...
(Date:2/9/2016)... ... February 09, 2016 , ... PharmApprove announced ... the National Organization for Rare Disorders (NORD). Dorman will lead PharmApprove efforts to ... heard throughout the drug regulatory review process. , “Adding Diane Dorman is just ...
(Date:2/9/2016)... and LONDON , February 9, 2016 ... bio tech replace paper and protect IP ... electronic laboratory notebook (ELN) will be rolled out in ... research and development (R&D) and protect valuable IP. Users will ... follow a specific researcher or experiment as part of the ...
(Date:2/9/2016)... LONDON , Feb. 9, 2016 /PRNewswire/ ... (PTP1B) Inhibitors-Pipeline Insights, 2016", report provides in ... their development activities around the Protein-Tyrosine Phosphatase ... the product profiles in various stages of ... Phase II, Phase III and Preregistration. Report ...
Breaking Biology Technology:
(Date:1/25/2016)...   Unisys Corporation (NYSE: UIS ) today announced ... International Airport, New York City , to help ... to enter the United States using passports ... pilot testing of the system at Dulles last year. The ... during January 2016. --> pilot testing of the ...
(Date:1/22/2016)... , Jan. 22, 2016 ... addition of the "Global Biometrics Market ... their offering. --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ... "Global Biometrics Market in Retail Sector ... --> Research and Markets ( ...
(Date:1/20/2016)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce the attainment of record-setting corporate ... of the company,s laser focus on (and growing international ... comprehensive, easy-to-use and highly affordable cloud-based technology platform. ... growth achievements in 2015 include: , Record ...
Breaking Biology News(10 mins):